AstraZeneca wins approval for new diabetes drug
The FTSE 100 pharmaceuticals firm, AstraZeneca, has won Europe-wide approval for its diabetes drug Komboglyze.
The FTSE 100 pharmaceuticals firm, AstraZeneca, has won Europe-wide approval for its diabetes drug Komboglyze.
The treatment, which was developed in conjunction with US peer Bristol-Myers Squibb, helps glycaemic control in adult patients with type 2 diabetes.
The approval comes following a study involving 4,326 patients.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Type 2 diabetes accounts for approximately 90 to 95% of all cases of diagnosed diabetes in adults. In Europe alone there are around 50 million people suffering with the condition.
The share price fell marginally by 0.04% to 2,820p by 08:20.
BS
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
What MoneyWeek writers read and watched in 2024
Here's a roundup of MoneyWeek's favourite books, films and TV shows in 2024
By Dr Matthew Partridge Published
-
Why Saba is trying to take advantage of UK investment trusts
Max King looks at why ever-widening discounts may have created an opportunity for Saba Investments in the UK world of investment trusts
By Max King Published